Novel PPARγ agonists GI 262570, GW 7845, GW 1929, and pioglitazone decrease calcium channel function and myogenic tone in rat mesenteric arteries

Pharmacology

Volumn 73, Issue 1, 2005, Pages 15-22

  Heppner, Thomas J ^a   Bonev, Adrian D ^a   Eckman, Delrae M ^b   Gomez, Maria F ^c   Petkov, Georgi V ^a   Nelson, Mark T ^a  

^a UNIVERSITY OF VERMONT   (United States)

^b WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^c LUND UNIVERSITY   (Sweden)

Author keywords

Calcium activated K+ channels; Peroxisome proliferator activated receptors; Voltage dependent calcium channels

Indexed keywords

2 [1 CARBOXY 2 [4 [2 (5 METHYL 2 PHENYL 4 OXAZOLYL)ETHOXY]PHENYL] ETHYLAMINO]BENZOIC ACID METHYL ESTER; 2 [1 CARBOXY 2 [4 [2 (5 METHYL 2 PHENYL 4 OXAZOLYL)ETHOXY]PHENYL]ETHYLAMINO]BENZOIC ACID METHYL ESTER; CALCIUM CHANNEL L TYPE; FARGLITAZAR; N (2 BENZOYLPHENYL) O [2 (METHYL 2 PYRIDINYLAMINO)ETHYL]TYROSINE; NISOLDIPINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; BARIUM; BENZOPHENONE DERIVATIVE; CALCIUM CHANNEL; DRUG DERIVATIVE; OXAZOLE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TYROSINE;

ANIMAL CELL; ANIMAL TISSUE; ARTERY DIAMETER; ARTERY DILATATION; ARTERY TONE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; MESENTERIC ARTERY; NONHUMAN; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE FIBER; ALGORITHM; ANIMAL; BLOOD PRESSURE; CELL MEMBRANE POTENTIAL; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; ELECTROPHYSIOLOGY; IN VITRO STUDY; METABOLISM; MUSCLE CELL; MUSCLE TONE; PATCH CLAMP; SPRAGUE DAWLEY RAT; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ALGORITHMS; ANIMALS; BARIUM; BENZOPHENONES; BLOOD PRESSURE; CALCIUM CHANNELS; ELECTROPHYSIOLOGY; FEMALE; HYPOGLYCEMIC AGENTS; MEMBRANE POTENTIALS; MESENTERIC ARTERIES; MUSCLE CELLS; MUSCLE TONUS; MUSCLE, SMOOTH, VASCULAR; OXAZOLES; PATCH-CLAMP TECHNIQUES; PPAR GAMMA; RATS; RATS, SPRAGUE-DAWLEY; THIAZOLIDINEDIONES; TYROSINE; VASODILATION;

EID: 10844281766     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081070     Document Type: Article

References (41)

1. Martens FJAC, Visseren FLJ, Lemay J, deKoning EJP, Rabelink TJ: Metabolic and additional vascular effects of thiazolidinediones. Drugs 2002;62:1463-1480.
2. Meigs JB, Mittleman MA, Nathan, DM, Tofler GH, Singer DE, Murphy-Sheehy PM, Lipinska I, D'Agostino RB, Wilson PWF: Hyperinsulinemia, hyperglycemia, and impaired hemostasis: The Framingham Offspring Study. JAMA 2000;283:221-228.
3. Osei K: Insulin resistance and systemic hypertension. Am J Cardiol 1999;84:33J-36J.
4. Rao G: Insulin resistance syndrome. Am Fam Phys 2001;63:1159-1163.
5. Willson TM, Brown PJ, Sternbach DD, Henke BR: The PPARs: From orphan receptors to drug discovery. J Med Chem 2000:43:527-550.
6. Hoffman C, Colca JR: New oral thiazolidinedione antidiabetic agents act as insulin sensitizers. Diabetes Care 1992;15:1075-1078.
7. Ikeda HS, Taketoni S, Sugiyama Y, Shimura Y, Sohda T, Meguro K, Fujita T: Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals. Arzneimittelforschung 1990;40:156-162.
8. Kemnitz JW, Elson DF, Roecker EB, Baum ST, Bergman RN, Meglasson MD: Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure in obese, insulin-resistant rhesus monkeys. Diabetes 1994;43:204-211.
9. Iwamoto Y, Kuzuya T, Matsuda A, Awata T, Kumakura S, Inooka G, Shiraishi L: Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care 1991;14:1083-1086.
10. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994;331:188-1193.
11. Buchanan TA, Meehan WP, Jeng YY, Yang D, Chan TM, Nadler JL, Scott S, Rude RK, Hsueh WA: Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect. J Clin Invest 1995;96:354-360.
12. Dubey RK, Zhang HY, Reddy SR, Boegehold MA, Kotchen TA: Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats. Am J Physiol 1993;265:R726-R732.
13. Ogihara T, Rakugi H, Ikegami H, Mikami H, Masuo K: Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 1995;8:316-320.
14. Sung BH, Izzo JL, Dandona P, Wilson MF: Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus. Hypertension 1999;34:83-88.
15. Yoshimoto T, Naruse M, Nishikawa M, Naruse K, Tanabe A, Seki T, Imaki T, Demura R, Aikawa E, Demura H: Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats. Am J Physiol 1997;272:E989-E996.
16. Goud C, Pitt B, Webb RC, Richey JM: Synergistic actions of insulin and troglitazone on contractility in endothelium-denuded rat aortic rings. Am J Physiol 1998;275:E882-E887.
17. Kawasaki J, Hirano K, Nishimura J, Fujishima M, Kanaide H: Mechanisms of vasorelaxation induced by troglitazone, a novel antidiabetic drug, in the porcine coronary artery. Circulation 1998;98:2446-2452.
18. Peuler JD, Miller JA, Bourghli M, Zammam HY, Soltis EE, Sowers JR: Disparate effects of antidiabetic drugs on arterial contraction. Metabolism 1997;46:1199-1205.
19. 2+ currents and not endothelial nitric oxide production. Diabetes 1997;46:659-664.
20. Walker AB, Naderali EK, Chattington PD, Buckingham RE, Williams G: Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro. Diabetes 1998;47:810-814.
21. Arima S, Kohagura K, Takeuchi K, Taniyama Y, Sugawara A, Ikeda Y, Abe M, Omata K, Ito S: Biphasic vasodilator action of trogilitazone on the renal microcirculation. J Am Soc Nephrol 2002;13:342-349.
22. Hayashi K, Kanda T, Homma K, Tokuyama H, Okubo K, Takamatsu I, Tatematsu S, Kumagai H, Saruta T: Altered renal microvascular response in Zucker obese rats. Metabolism 2002;51:1553-1561.
23. Knock GA, Santosh KM, Aaronson PL: Differential effects of insulin-sensitizers troglitazone and rosiglitazone on ion currents in rat vascular myocytes. Eur J Pharmacol 1999;368:103-109.
24. Zhang F, Sowers JR, Ram JL, Standley PR, Peuler JD: Effects of pioglitazone on calcium channels in vascular smooth muscle. Hypertension 1994;24:170-175.
25. Triggle DJ: Calcium, calcium channels, and calcium channel antagonists. Can J Physiol Pharmacol 1990;68:1474-1481.
26. Nelson MT, Patlak JB, Worley JF, Standen NB: Calcium channels, potassium channels, and voltage dependence on arterial smooth muscle tone. Am J Physiol 1990;259:C3-C18.
27. 2+] in cerebral arteries of rat by membrane potential and intravascular pressure. J Physiol (Lond) 1998;508:199-209.
28. Cobb JE, Blanchard SG, Boswell EG, Brown KK, Charifson PS, Cooper JP, Collins JL, Dezube M, Henke BR, Hull-Ryde EA, Lake DH, Lenhard JM, Oliver W Jr, Oplinger J, Pentti M, Parks DJ, Plunket KD, Tong WQ: N-(2-benzoylphenyl)-L- tyrosine PPARγ agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent. J Med Chem 1998;41:5055-5069.
29. Collins JL, Blanchard SG, Boswell GE, Charifson PS, Cobb JE, Henke BR, Hull-Ryde EA, Kazmierski WM, Lake DH, Leesnitzer LM, Lehmann J, Lenhard JM, Orband-Miller LA, Gray-Nunez Y, Parks DJ, Plunkett KD, Tong W-Q: N-(2-benzoylphenly)-L-tyrosine PPARγ agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety. J Med Chem 1998;41:5037-5054.
30. Henke BR, Blanchard SG, Brackeen MF, Brown KK, Cobb JE, Collins JL, Harrington WW Jr, Hashim MA, Hull-Ryde EA, Kaldor I, Kliewer SA, Lake DH, Leesnitzer LM, Lehmann JM, Lenhard JM, Orband-Miller LA, Miller JF, Mook RA Jr, Noble SA, Oliver W Jr, Parks DJ, Plunket KD, Szewczyk JR, Willson TM: N-(2-benzoylphenly)-L-tyrosine PPARγ agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. J Med Chem 1998;41:5020-5036.
31. Nelson MT, Worley JF: Dihydropyridine inhibition of single calcium channels and contraction in rabbit mesenteric artery depends on voltage. J Physiol (Lond) 1989;412:65-91.
32. Berger J, Bailey P, Biwsas C, Cullinan CA, Doegbber TW, Hayes NS, Saperstein R, Smith RG, Leibowitz MD: Thizolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-γ: Binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology 1996;137:4189-4195.
33. Willson TM, Cobb JE, Cowan DJ, Wiethe RW, Correa ID, Prakash SR, Beck KD, Moore LB, Kliewer SA, Lehmann JM: The structure-activity relationship between peroxisome proliferator-activated receptor-γ agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 1996;39:665-668.
34. Brown KK, Henke BR, Blanchard SG, Cobb JE, Mook R, Kaldor I, Kliewer SA, Lehmann JM, Lenhard JM, Harrington WW, Novak PJ, Faison W, Binz JG, Hashim MA, Oliver WO, Brown HR, Parks DJ, Plunket KD, Tong WQ, Menius JA, Adkison K, Noble SA, Willson TM: A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-γ reverses the diabetic phenotype of the Zucker diabetic fatty rat. Diabetes 1999;48:1415-1424.
35. Eto K, Ohya Y, Nakamura Y, Abe I, Fujishima M: Comparative actions of insulin sensitizers on ion channels in vascular smooth muscle. Eur J Pharmacol 2001;423:1-7.
36. Nakamura Y, Ohya Y, Onaka U, Fujii K, Abe I, Fujishima M: Inhibitory action of insulin-sensitizing agents on calcium channels in smooth muscle cells from resistance arteries of guinea-pig. Br J Pharmacol 1998;123:675-682.
37. 2+ mobilization and cell proliferation in vascular smooth muscle cells. Br J Pharmacol 1999;128:673-683.
38. Mishra SK, Aaronson PI: Differential block by troglitazone and rosiglitazone of glibenclamide-sensitive K(+) current in rat aorta myocytes. Eur J Pharmacol 1999;386:121-125.
39. Brayden JE, Nelson MT: Regulation of arterial tone by activation of calcium-dependent potassium channels. Science 1992;256:532-535.
40. D'Angleo G, Meininger GA: Transduction mechanisms involved in the regulation of myogenic activity. Hypertension 1994;23:1096-1105.
41. Fu M, Zhang J, Xiaojun Z, Myles DE, Willson TM, Liu X, Chen YE: Peroxisome proliferator-activated receptor-γ inhibits transforming growth factor β-induced connective tissue growth factor expression in human aortic smooth muscle cells by interfering with Smad3. J Biol Chem 2001;276:45888- 45894.